Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab plus selinexor in relapsed/refractory CNS lymphoma
ChiCTR2500103713Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Jun 2025
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of glofitamab and selinexor in central nervous system lymphoma, primary central nervous system lymphoma (PCNSL) and secondary central nervous system lymphoma (SCNSL), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoint: progression free survival. Started Jun 2025; status: recruiting.
02
Drugs
glofitamabselinexor
03
Conditions
central nervous system lymphomaprimary central nervous system lymphoma (PCNSL)secondary central nervous system lymphoma (SCNSL)
Beyond the preview
Go deeper on ChiCTR2500103713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103713.